These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9763355)

  • 21. Homocysteine and essential hypertension.
    Rodrigo R; Passalacqua W; Araya J; Orellana M; Rivera G
    J Clin Pharmacol; 2003 Dec; 43(12):1299-306. PubMed ID: 14615465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction.
    van Guldener C; Stehouwer CD
    Semin Thromb Hemost; 2000; 26(3):281-9. PubMed ID: 11011845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia.
    Weiss N; Keller C; Hoffmann U; Loscalzo J
    Vasc Med; 2002 Aug; 7(3):227-39. PubMed ID: 12553746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homocysteine, platelet function and thrombosis.
    Di Minno G; Coppola A; Mancini FP; Margaglione M
    Haematologica; 1999 Jun; 84 Suppl EHA-4():61-3. PubMed ID: 10907470
    [No Abstract]   [Full Text] [Related]  

  • 25. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease.
    Boers GH
    Semin Thromb Hemost; 2000; 26(3):291-5. PubMed ID: 11011846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells.
    Midorikawa S; Sanada H; Hashimoto S; Watanabe T
    Biochem Biophys Res Commun; 2000 May; 272(1):182-5. PubMed ID: 10872824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homocysteine--relevant for atherogenesis?
    Kircher T; Sinzinger H
    Wien Klin Wochenschr; 2000 Jun; 112(12):523-32. PubMed ID: 10953870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Homocysteine. The cardiovascular risk factor of the next millennium?].
    Suárez García I; Gómez Cerezo JF; Ríos Blanco JJ; Barbado Hernández FJ; Vázquez Rodríguez JJ
    An Med Interna; 2001 Apr; 18(4):211-7. PubMed ID: 11496543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia.
    Sauls DL; Arnold EK; Bell CW; Allen JC; Hoffman M
    Thromb Res; 2007; 120(1):117-26. PubMed ID: 16979225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Homocysteine, a risk factor of atherosclerosis].
    Ambrosi P; Rolland P; Garçon D
    Arch Mal Coeur Vaiss; 1996 Dec; 89(12):1667-71. PubMed ID: 9137733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperhomocysteinemia and thrombosis.
    Guba SC; Fonseca V; Fink LM
    Semin Thromb Hemost; 1999; 25(3):291-309. PubMed ID: 10443960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic mild hyperhomocysteinemia induces aortic endothelial dysfunction but does not elevate arterial pressure in rats.
    Miao CY; Villeneuve N; Brunel-Jacquemin C; Petit C; Guillaumin JP; Gransagne D; Briant C; Vilaine JP; Vanhoutte PM
    J Vasc Res; 2005; 42(2):148-56. PubMed ID: 15713986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can mild-to-moderate hyperhomocysteinaemia impair endothelial function in the absence of other risk factors for cardiovascular disease?
    Honing ML; Stehouwer CD
    Clin Sci (Lond); 2004 Apr; 106(4):345-6. PubMed ID: 14656217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of hyperhomocysteinemia in nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation.
    Heil SG; De Vriese AS; Kluijtmans LA; Mortier S; Den Heijer M; Blom HJ
    Cell Mol Biol (Noisy-le-grand); 2004 Dec; 50(8):911-6. PubMed ID: 15704255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hyperhomocysteinemia: atherothrombosis and neurotoxicity].
    Fridman O
    Acta Physiol Pharmacol Ther Latinoam; 1999; 49(1):21-30. PubMed ID: 10797837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hyperhomocysteinaemia: physiopathology and medical implications].
    Torre Delgadillo A; Téllez Zenteno JF; Morales Buenrrostro LE
    Rev Invest Clin; 2000; 52(5):557-64. PubMed ID: 11195184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperhomocysteinemia and venous thrombosis.
    Bos GM; den Heijer M
    Semin Thromb Hemost; 1998; 24(4):387-91. PubMed ID: 9763356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.